WebThe validation cohort consisted of samples from a previously reported fully blinded, multi-center, retrospective study in which combination testing with ThyGeNEXT ® + ThyraMIR … *Testing algorithm based upon Bethesda Diagnostic Categories III (AUS/FLUS) … 1. Finkelstein SD, Sistrunk JW, Malchoff CD, et al. A retrospective evaluation of … The addition of genetic analysis to the evaluation of thyroid FNA samples … Effective April 1, 2024, ThyGeNEXT ® will be billed with Proprietary Laboratory … Interpace Diagnostics is committed to providing patients with access to … Corporate Offices: 855-776-6419 Client Services: 412-224-6900 Billing: 888-963 … WebApr 5, 2024 · Interpace has five commercialized molecular tests and one test in a clinical ... ThyGeNEXT® and ThyraMIR® reflex testing yields high predictive value in determining the presence and absence of ...
Interpace Biosciences Announces New Clinical Validation Data ...
WebMay 3, 2024 · Thomas W. Burnell, President and CEO of Interpace Biosciences, stated, “We are delighted that eviCore values the clinical utility of ThyGeNEXT and ThyraMIR, … WebAug 17, 2024 · Four molecular tests are now commercially available to provide a clearer cytological assessment of thyroid tumors: Afirma (Veracyte), ThyroSeq (CBLPath), … problems of foot drill
Interpace Biosciences Announces Improved Coverage for …
Web© 2024 Interpace Diagnostics: lims2-release-1.38.9-11824 [production] WebInterpace Diagnostic's robust support programs can help patients access the benefits of molecular testing for thyroid and pancreatic cancer. Learn more … WebJul 29, 2024 · Blue Shield originally granted coverage for ThyGeNEXT and ThyraMIR in March of 2024 and now members will be able to access Interpace’s molecular thyroid … problems of foreign policy analysis pdf